Skip to Main Content

SPS PGD template for the supply and/or administration of subcutaneous medroxyprogesterone acetate (SC-DMPA) injection for contraception.

Provenance

Written by SPS and the College of Sexual and Reproductive Health (CoSRH), with the support of specialist stakeholders working within clinical practice, for use within reproductive services.

Templates available

Version 3.0 of this PGD template, valid from May 2026, has been published to allow organisations to undertake local governance processes in a timely manner.

Version 2.3 of this PGD template remains currently valid and will be removed from this page on its expiry (30th April 2026).

PGD template attachment

The template PGD is attached below to download and use in conjunction with our implementation advice.

More reproductive health PGD templates

All PGD templates

National PGD, protocol and written instructions templates

National templates are developed with experts for clinical specialties. They reduce duplication and variation, and improve consistency of care.

Update history

  1. Version 3.0 published
  1. Planned review detail added
  1. Information added regarding name change of FSRH to CoSRH
  1. Version 2.3 PGD template added. Updated contraindications and cautions in line with SmPC changes.
  1. Updated PGD template published - statement added regarding a suggested link between the prolonged use of medroxyprogesterone acetate and a small increased risk of intracranial meningioma in line with FSRH statement. Added exclusion of meningioma as per SPC.
  1. Version 2.1 published - minor changes to align with updated FSRH guidance
  1. Expiring template removed.
  2. Title, URL and summary amended.
  1. Version 2.0 PGD template added
  1. Published